Clinical Trial Update: Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating amlexanox 0.5% oral rinse for radiation-induced oral mucositis in patients with head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• Amlexanox (amlexanox)

Snippet

Sponsor: Access Pharmaceuticals, Inc. | Conditions: Oral Mucositis | Phase 2 | Status: COMPLETED